American Journal of Clinical Dermatology

, Volume 4, Issue 5, pp 297–305 | Cite as

Chronic Urticaria

A Role for Newer Immunomodulatory Drugs?
  • Alberto Tedeschi
  • Lorena Airaghi
  • Maurizio Lorini
  • Riccardo Asero
Leading Article


Chronic urticaria is now recognized as an autoreactive disorder in a substantial fraction of patients. A serologic mediator of whealing has been demonstrated in 50–60% of patients with chronic urticaria, and autoantibodies against the high affinity IgE receptor or IgE have been detected in about half of these patients. The demonstration that chronic urticaria is frequently autoimmune has encouraged a more aggressive therapeutic approach, with the use of immunomodulatory drugs.

A step-by-step approach to the management of chronic urticaria is proposed, based on our personal experience and review of current medical literature, identified through Medline research and hand searching in medical journals.

The non- or low-sedating H1 receptor antagonists (antihistamines), such as cetirizine, fexofenadine, loratadine, mizolastine and, more recently, levocetirizine, desloratadine and ebastine, represent the basic therapy for all chronic urticaria patients. Older sedating antihistamines, such as hydroxyzine and diphenhydramine, may be indicated if symptoms are severe, are associated with angioedema, and if the patient is anxious and disturbed at night.

Corticosteroid therapy with prednisone or methylprednisolone can be administered for a few days (7–14) if urticarial symptoms are not controlled by antihistamines and a rapid clinical response is needed. In cases of relapse after corticosteroid suspension, leukotriene receptor antagonists, such as montelukast and zafirlukast, should be tried. In our experience, remission of urticarial symptoms can be achieved in 20–50% of chronic urticaria patients unresponsive to antihistamines alone. When urticaria is unremitting and is not controlled by combined therapy with antihistamines and leukotriene receptor antagonists, prolonged corticosteroid therapy may be needed. Long-term corticosteroid therapy should be administered at the lowest dose able to control urticarial symptoms, in order to minimize adverse effects. In a few patients, however, high-dose corticosteroid therapy may have to be administered for long periods. In these patients, immunosuppressive treatment with low-dose cyclosporine can be started. This type of treatment has a corticosteroid-sparing effect and is also generally effective in patients with severe, unremitting urticaria, but requires careful monitoring of cyclosporine plasma concentration and possible adverse effects.

Other immunomodulating drugs that have been tried in chronic urticaria patients include hydroxychloroquine, dapsone, sulfasalazine and methotrexate, but their efficacy has not been proven in large controlled studies. Warfarin therapy may also be considered in some patients with chronic urticaria and angioedema unresponsive to antihistamines.


  1. 1.
    Greaves MW. Chronic urticaria. N Engl J Med 1995; 332: 1767–1772PubMedCrossRefGoogle Scholar
  2. 2.
    Greaves M. Chronic urticaria. J Allergy Clin Immunol 2000; 105: 664–672PubMedCrossRefGoogle Scholar
  3. 3.
    Kaplan AP. Chronic urticaria and angioedema. N Engl J Med 2002; 346: 175–179PubMedCrossRefGoogle Scholar
  4. 4.
    May CD. Are confusion and controversy about food hypersensitivity really necessary? J Allergy Clin Immunol 1985; 75: 329–333PubMedCrossRefGoogle Scholar
  5. 5.
    Doeglas HMG. Reactions to aspirin and food additives in patients with chronic urticaria including the physical urticarias. Br J Dermatol 1975; 93: 135–144PubMedCrossRefGoogle Scholar
  6. 6.
    Kaplan AP. Urticaria and angioedema. In: Middleton Jr E, Reed CE, Ellis EF, et al., editors. Allergy: principles & practice. 5th ed., vol 2, St Louis: Mosby-Year book, 1998: 1104–1122Google Scholar
  7. 7.
    Zuberbier T, Chantraine-Hess S, et al. Pseudoallergen-free diet in the treatment of chronic urticaria: a prospective study. Acta Derm Venereol 1995; 75: 484–487PubMedGoogle Scholar
  8. 8.
    Pigatto PD, Valsecchi RH. Chronic urticaria: a mystery. Allergy 2000; 55: 306–308PubMedCrossRefGoogle Scholar
  9. 9.
    Zuberbier T, Pfrommer C, Specht K, et al. Aromatic components of food as novel eliciting factors of pseudoanergic reactions in chronic urticaria. J Allergy Clin Immunol 2002; 109: 343–348PubMedCrossRefGoogle Scholar
  10. 10.
    Di Campli C, Gasbarrini A, Nucera E, et al. Beneficial effects of Helicobacter pylori eradication on idiopathic chronic urticaria. Dig Dis Sci 1998; 43: 1226–1229CrossRefGoogle Scholar
  11. 11.
    Sakurane M, Shiotani A, Furukawa F. Therapeutic effects of antibacterial treatment for intractable skin diseases in Helicobacter pylori-positive Japanese patients. J Dermatol 2002; 29: 23–27PubMedGoogle Scholar
  12. 12.
    Wedi B, Kapp A. Helicobacter pylory infection in skin diseases: a critical appraisal. Am J Clin Dermatol 2002; 3: 273–282PubMedCrossRefGoogle Scholar
  13. 13.
    Schnyder B, Hebling A, Pichler WI. Chronic idiopathic urticaria: natural course and association with Helicobacter pylori infection. Int Arch Allergy Immunol 1999; 119: 60–63PubMedCrossRefGoogle Scholar
  14. 14.
    Habte-Gabr E, Timneh M, Hailu M. Chronic urticaria: its relationship to intestinal parasitic infestation and response to antihelmintic drugs: a preliminary study. Ethiop Med J 1977; 15: 9–14PubMedGoogle Scholar
  15. 15.
    Oteifa NM, Moustafa MA, Elgozamy BM. Toxocariasis as a possibile cause of allergic diseases in children. J Egypt Soc Parasitol 1998; 28: 365–372PubMedGoogle Scholar
  16. 16.
    Grattan CE, Wallington TB, Warin RP, et al. A serological mediator in chronic idiopathic urticaria: a clinical, immunological and histological evaluation. Br J Dermatol 1986; 114: 583–590PubMedCrossRefGoogle Scholar
  17. 17.
    Gruber BL, Baeza ML, Marchese MJ, et al. Prevalence and functional role of anti-IgE autoantibodies in urticarial syndromes. J Invest Dermatol 1988; 90: 213–217PubMedCrossRefGoogle Scholar
  18. 18.
    Grattan CEH, Francis DM, Hide M, et al. Detection of circulating histamine releasing autoantibodies with functional properties of anti IgE in chronic urticaria. Clin Exp Allergy 1991; 21: 695–704PubMedCrossRefGoogle Scholar
  19. 19.
    Hide M, Francis DM, Grattan CEH, et al. Autoantibodies against the high-affinity IgE receptor as a cause of histamine release in chronic urticaria. N Engl J Med 1993; 328: 1599–1604PubMedCrossRefGoogle Scholar
  20. 20.
    Fiebiger E, Maurer D, Holub H, et al. J. Serum IgG autoantibodies directed against the alpha chain of FcεRI: a selective marker and pathogenetic factor for a distinct subset of chronic urticaria patients? J Clin Invest 1995; 96: 2606–2612PubMedCrossRefGoogle Scholar
  21. 21.
    Ferrer M, Kinet JP, Kaplan AP. Comparative studies of functional and binding assays for IgG anti-FcεRIα (α-subunit). J Allergy Clin Immunol 1998; 101: 672–676PubMedCrossRefGoogle Scholar
  22. 22.
    Ferrer M, Nakazawa K, Kaplan AP. Complement dependence of histamine release in chronic urticaria. J Allergy Clin Immunol 1999; 104: 169–172PubMedCrossRefGoogle Scholar
  23. 23.
    Kikuchi Y, Kaplan AP. A role for C5a in augmenting IgE-dependent histamine release from basophils in chronic urticaria. J Allergy Clin Immunol 2002; 109: 114–118PubMedCrossRefGoogle Scholar
  24. 24.
    Zuberbier T, Henz BM, Fiebiger E, et al. Anti-FcεRIα serum autoantibodies in different subtypes of urticaria. Allergy 2000; 55: 9511–9514CrossRefGoogle Scholar
  25. 25.
    Stadler BM, Miescher S, Horn M, et al. Allergic manifestations as the results of a conditional autoimmune response. Int Arch Allergy Immunol 2001; 124: 411–413PubMedCrossRefGoogle Scholar
  26. 26.
    Horn MP, Pachlopnik JM, Vogel M, et al. Conditional autoimmunity mediated by human natural anti-FcεRI alpha autoantibodies? FASEB J 2001; 15: 2268–2274PubMedCrossRefGoogle Scholar
  27. 27.
    Elias J, Boss E, Kaplan AP. Studies of the cellular infiltrate of chronic idiopathic urticaria: prominence of T -lymphocytes, monocytes, and mast cells. J Allergy Clin Immunol 1986; 78: 914–918PubMedCrossRefGoogle Scholar
  28. 28.
    Sabroe RA, Poon E, Orchard GE, et al. Cutaneous inflammatory cell infiltrate in chronic idiopathic urticaria: comparison of patients with and without antiFcεRIa or anti-IgE autoantibodies. J Allergy Clin Immunol 1999; 103: 484–493PubMedCrossRefGoogle Scholar
  29. 29.
    Wedi B, Novacevic V, Koerner M, et al. Chronic urticaria serum induces histamine release, leukotriene production, and basophil CD63 surface expression: inhibitory effects of anti-inflammatory drugs. J Allergy Clin Immunol 2000; 105: 552–560PubMedCrossRefGoogle Scholar
  30. 30.
    Maxwell DL, Atkinson BA, Spur BW, et al. Skin responses to intradermal histamine and leukotrienes C4, D4, and E4 in patients with chronic idiopathic urticaria and in normal subjects. J Allergy Clin Immunol 1990; 86: 759–765PubMedCrossRefGoogle Scholar
  31. 31.
    Cunningham F. Lipid mediators in inflammatory skin disorders. J Lipid Mediat 1990; 2: 61–74PubMedGoogle Scholar
  32. 32.
    Norris JG, Sullivan TI. Leukotriene and cytokines in steroid dependent chronic urticaria [abstract]. J Allergy Clin I mmun 01 1998; 101 (Pt 2): S128Google Scholar
  33. 33.
    Irani C, Gordon ND, Zweiman B, et al. Chronic urticaria/angioedema and Graves’ disease: coexistence of 2 antireceptor antibody-mediated diseases. J Allergy Clin Immunol 2001; 108: 874PubMedCrossRefGoogle Scholar
  34. 34.
    Leznoff A, Sussman GL. Syndrome of idiopathic chronic urticaria and angioedema with thyroid autoimmunity: a study of 90 patients. J Allergy Clin Immunol 1989; 84: 66–71PubMedCrossRefGoogle Scholar
  35. 35.
    Bar-Sela S, Reshef T, Mekori Y. IgE antithyroid microsomal antibodies in a patient with chronic urticaria. J Allergy Clin Immunol 1999; 103: 1216–1217PubMedCrossRefGoogle Scholar
  36. 36.
    Tedeschi A, Lorini M, Asero R. Anti-thyroid peroxidase IgE in patients with chronic urticaria. J Allergy Clin Immunol 2001; 108: 467–468PubMedCrossRefGoogle Scholar
  37. 37.
    Asero R, Tedeschi A, Lorini M, et al. Chronic urticaria: clinical and serological aspects. Clin Exp Allergy 2001; 31: 1105–1110PubMedCrossRefGoogle Scholar
  38. 38.
    Greaves MW, O’Donnen BF. Not an chronic urticaria is “idiopathic”. Exp Dermatol 1998; 7: 11–13PubMedCrossRefGoogle Scholar
  39. 39.
    Fagiolo U, Kricek F, Ruf C, et al. Effects of complement inactivation and IgG depletion on skin reactivity to autologous serum in chronic idiopathic urticaria. J Allergy Clin Immunol 2000; 106: 567–572PubMedCrossRefGoogle Scholar
  40. 40.
    Kermani F, Niimi N, Francis DM, et al. Characterization of a novel mast-cell specific histamine releasing activity in chronic idiopathic urticaria (CIU) [abstract]. J Invest Dermatol 1995; 105: 452Google Scholar
  41. 41.
    Claveau J, Lavoie A, Brunet C, et al. Chronic idiopathic urticaria: possible contribution of histamine releasing factor to the pathogenesis. J Allergy Clin Immunol 1993; 92: 132–137PubMedCrossRefGoogle Scholar
  42. 42.
    Sabroe RA, Grattan CE, Francis DM, et al. The autologous serum skin test: a screening test for autoantibodies in chronic idiopathic urticaria. Br J Dermatol 1999; 140: 446–452PubMedCrossRefGoogle Scholar
  43. 43.
    Ring J, Brockow K, Ollert M, et al. Antihistamines in urticaria. Clin Exp Allergy 1999; 29 Suppl. 1: 31–37PubMedCrossRefGoogle Scholar
  44. 44.
    Kalivas J, Breneman D, Tharp D, et al. Urticaria: clinical efficacy of cetirizine in comparison with hydroxyzine and placebo. J Allergy Clin Immunol 1990; 86: 1014–1018PubMedCrossRefGoogle Scholar
  45. 45.
    Breneman DL. Cetirizine versus hydroxyzine and placebo in chronic idiopathic urticaria. Ann Pharmacother 1996; 30: 1075–1079PubMedGoogle Scholar
  46. 46.
    Finn Jr AF, Kaplan AP, Fretwell R, et al. A double-blind, placebo-controlled trial of fexofenadine HCl in the treatment of chronic idiopathic urticaria. J Allergy Clin Immunol 1999; 103: 1071–1078CrossRefGoogle Scholar
  47. 47.
    Monroe EW. Loratadine in the treatment of urticaria. Clin Ther 1997; 19: 232–242PubMedCrossRefGoogle Scholar
  48. 48.
    Lorette G, Giannetti A, Pereira RS, et al. One-year treatment of chronic urticaria with mizolastine: efficacy and safety. URTOL study group. J Eur Acad Dermatol Venereol 2000; 14: 83–90PubMedCrossRefGoogle Scholar
  49. 49.
    Kalis B. Double-blind multicentre comparative study of ebastine, terfenadine and placebo in the treatment of chronic idiopathic urticaria in adults. Drugs 1996; 52 Suppl. 1: 30–34PubMedCrossRefGoogle Scholar
  50. 50.
    Ring J, Hein R, Gauger A. Desloratadine in the treatment of chronic idiopathic urticaria. Allergy 2001; 56 Suppl. 65: 28–32PubMedCrossRefGoogle Scholar
  51. 51.
    Clough GF, Boutsiouki P, Church MK. Comparison of the effects of levocetirizine and loratadine on histamine-induced wheal, flare and itch in human skin. Allergy 2001; 56: 985–988PubMedCrossRefGoogle Scholar
  52. 52.
    Gandon JM, Allain H. Lack of effect of single and repeated doses of levocetirizine, a new antihistamine drug, on cognitive and psychomotor functions in healthy volunteers. Br J Clin Pharmacol 2002; 54: 51–58PubMedCrossRefGoogle Scholar
  53. 53.
    Zuberbier T, Greaves MW, Juhlin L, et al. Management of urticaria: a consensus report. J Investig Dermatol Symp Proc 2001; 6: 128–131PubMedCrossRefGoogle Scholar
  54. 54.
    Chowdhury BA. Chronic urticaria and angioedema. N Engl J Med 2002; 347: 220–221PubMedCrossRefGoogle Scholar
  55. 55.
    Goldsobel AB, Rohr AS, Siegel SC, et al. Efficacy of doxepin in the treatment of chronic idiopathic urticaria. J Allergy Clin Immunol 1986; 78: 867–873PubMedCrossRefGoogle Scholar
  56. 56.
    Harvey RP, Wegs J, Schocket AL. A controlled trial of therapy in chronic urticaria. J Allergy Clin Immunol 1981; 68: 262–266PubMedCrossRefGoogle Scholar
  57. 57.
    Commens CA, Greaves MW. Cimetidine in chronic idiopathic urticaria: a randomised double-blind study. Br J Dermatol 1978; 99: 675–676PubMedCrossRefGoogle Scholar
  58. 58.
    Bleehen SS, Thomas SE, Greaves MW, et al. Cimetidine and chlorpheniramine in the treatment of chronic idiopathic urticaria: a multi-centre randomized double-blind study. Br J Dermatol 1987; 117: 81–88PubMedCrossRefGoogle Scholar
  59. 59.
    Simons FE, Sussman GL, Simons KJ. Effect of the H2-antagonist cimetidine on the pharmacokinetics and pharmacodynamics of the HI-antagonists hydroxyzine and cetirizine in patients with chronic urticaria. J Allergy Clin Immunol 1995; 95: 685–693PubMedCrossRefGoogle Scholar
  60. 60.
    Lewis RA, Austen KF, Soberman RJ. Leukotrienes and other products of the 5-lipoxygenase pathway. N Engl J Med 1990; 323: 645PubMedCrossRefGoogle Scholar
  61. 61.
    Spector S, Tan RA. Antileukotrienes in chronic urticaria [letter]. J Allergy Clin Immunol 1998; 101: 572PubMedCrossRefGoogle Scholar
  62. 62.
    Ellis NlH. Successful treatment of chronic urticaria with leukotriene antagonists. J Allergy Clin Immunol 1998; 102: 876–877PubMedCrossRefGoogle Scholar
  63. 63.
    Chu TJ, Warren MS. Zafirlukast (ACCOLATE®) in the treatment of chronic idiopathic urticaria: a case series [abstract]. J Allergy Clin Immunol 1998; 101 (part 2): S155Google Scholar
  64. 64.
    Pacor ML, Di Lorenzo G, Corrocher R. Efficacy of leukotriene receptor antagonist in chronic urticaria: a double-blind, placebo-controlled comparison of treatment with montelukast and cetirizine in patients with chronic urticaria with intolerance to food additive and/or acetylsalicylic acid. Clin Exp Allergy 2001; 31: 1607–1614PubMedCrossRefGoogle Scholar
  65. 65.
    Bensch G, Borish L. Leukotriene modifiers in chronic urticaria. Ann Allergy Asthma Immunol 1999; 83: 348PubMedCrossRefGoogle Scholar
  66. 66.
    Berkun Y, Shalit M. Successful treatment of delayed pressure urticaria with monte1ukast. Allergy 2000; 55 (2): 203–204PubMedCrossRefGoogle Scholar
  67. 67.
    Tedeschi A, Lorini M, Suli C, et al. Successful treatment of chronic urticaria. Allergy 2000; 55: 1097–1098PubMedCrossRefGoogle Scholar
  68. 68.
    Erbagci Z. The leukotriene receptor antagonist montelukast in the treatment of chronic idiopathic urticaria: a single-blind, placebo-controlled, crossover clinical study. J Allergy Clin Immunol 2002; 110 (3): 484–488PubMedCrossRefGoogle Scholar
  69. 69.
    Reimers A, Pichler C, Helbling A, et al. Zafirlukast has no beneficial effects in the treatment of chronic urticaria. Din Exp Allergy 2002; 32 (12): 1763–1768CrossRefGoogle Scholar
  70. 70.
    Asero R, Tedeschi A, Lorini M. Leukotriene receptors antagonists in chronic urticaria. Allergy 2001; 56: 456–457PubMedCrossRefGoogle Scholar
  71. 71.
    Asero R. Leukotriene receptor antagonists may prevent NSAID-induced exacerbations in patients with chronic urticaria. Ann Allergy Asthma Immunol 2000; 85: 156–157PubMedCrossRefGoogle Scholar
  72. 72.
    Fradin MS, Ellis CN, Goldfarb MT, et al. Oral cyclosporine for severe chronic idiopathic urticaria and angioedema. J Am Acad Dermatol 1991; 25: 1065–1067PubMedCrossRefGoogle Scholar
  73. 73.
    Toubi E, Blant A, Kessel A, et al. Low-dose cyclosporin A in the treatment of severe chronic idiopathic urticaria. Allergy 1997; 52: 312–316PubMedCrossRefGoogle Scholar
  74. 74.
    Barlow RJ, Kobza Black A, et al. Treatment of severe, chronic urticaria with cyclosporin A. Eur J Dermatol 1993; 3: 273–275Google Scholar
  75. 75.
    Grattan CEH, O’Donnel BF, Francis DM, et al. Randomized double-blind study of cyclosporin in chronic “idiopathic” urticaria. Br J Dermatol 2000; 143: 365–372PubMedCrossRefGoogle Scholar
  76. 76.
    Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 2001; 345: 747–755PubMedCrossRefGoogle Scholar
  77. 77.
    Mouthon L, Kaveri SV, Spalter SH, et al. Mechanisms of action of intravenous immune globulin in immune-mediated diseases. Clin Exp Immunol 1996; 104 Suppl. 1: 3–9PubMedGoogle Scholar
  78. 78.
    O’Donnen BF, Barr RM, Black AK, et al. Intravenous immunoglobulin in chronic autoimmune urticaria. Br J Dermatol 1998; 138: 101–106CrossRefGoogle Scholar
  79. 79.
    Asero R. Are IVIG for chronic unremitting urticaria effective? Allergy 2000; 55: 1099–1101PubMedCrossRefGoogle Scholar
  80. 80.
    Grattan CEH, Francis DM, Slater NGP, et al. Plasmapheresis for severe unremitting chronic urticaria. Lancet 1992; 339: 1078–1080PubMedCrossRefGoogle Scholar
  81. 81.
    Gach JE, Sabroe RA, Greaves MW, et al. Methotrexate-responsive chronic idiopathic urticaria: a report of two cases. Br J Dermatol 2001; 145: 340–343PubMedCrossRefGoogle Scholar
  82. 82.
    Lopez LR, Davis KC, Kohler PF, et al. The hypocomplementemic urticarialvasculitis syndrome: therapeutic response to hydroxychloroquine-. J Allergy Clin Immunol 1984; 73: 600–603PubMedCrossRefGoogle Scholar
  83. 83.
    Jaffer AM. Sulfasalazine in the treatment of corticosteroid-dependent chronic idiopathic urticaria. J Allergy Clin Immunol 1991; 88: 964–965PubMedCrossRefGoogle Scholar
  84. 84.
    Hartmann K, Hani N, Hinrichs R, et al. Successful sulfasalazine treatment of severe chronic idiopathic urticaria associated with pressure urticaria [letter]. Acta Derm Venereol 2001; 81: 71PubMedCrossRefGoogle Scholar
  85. 85.
    Boehm I, Bauer R, Bieber T. Urticaria treated with dapsone. Allergy 1999; 54: 765–766PubMedCrossRefGoogle Scholar
  86. 86.
    Rumbyrt JS, Katz JL, Schocket AL. Resolution of chronic urticaria in patients with thyroid autoimmunity. J Allergy Clin Immunol 1995; 96: 901–905PubMedCrossRefGoogle Scholar
  87. 87.
    Heymann WR. Chronic urticaria and angioedema associated with thyroid autoimmunity: review and therapeutic implications. J Am Acad Dermatol 1999; 40: 229–232PubMedCrossRefGoogle Scholar
  88. 88.
    Kandeel AA, Zeid M, Helm T, et al. Evaluation of chronic urticaria in patients with Hashimoto thyroiditis. J Clin Immunol 2001; 21: 335–347PubMedCrossRefGoogle Scholar
  89. 89.
    Berth-Jones J, Hutchinson PE, Wicks ACB, et al. Chronic urticaria with angioedema controlled by warfarin. BMJ 1988; 297: 1382–1383PubMedCrossRefGoogle Scholar
  90. 90.
    Barlow RJ, Greaves MW. Warfarin in the treatment of chronic urticaria/angiooedema. Br J Dermatol 1992; 126: 415–416PubMedCrossRefGoogle Scholar
  91. 91.
    Parslew R, Pryce D, Ashworth J, et al. Warfarin treatment of chronic idiopathic urticaria and angio-oedema. Clin Exp Allergy 2000; 30: 1161–1165PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 2003

Authors and Affiliations

  • Alberto Tedeschi
    • 1
  • Lorena Airaghi
    • 1
  • Maurizio Lorini
    • 1
  • Riccardo Asero
    • 2
  1. 1.Allergy and Immunopharmacology UnitFirst Division of Internal Medicine, Padiglione Granelli, IRCCS Ospedale Maggiore PoliclinicoMilanItaly
  2. 2.Allergy UnitClinica S. Carlo, Paderno DugnanoMilanItaly

Personalised recommendations